Interviews

4D Molecular Therapeutics

Nexus aims to complement mechanical recycling through advanced processes by managing many of today’s plastic formats, such as films, flexible packaging and foams, which often end in landfills. This approach addresses the limitations of current recycling methods, improving the overall recycling ecosystem and with it, the perception of plastics and plastics recycling.

David Kirn

Co-Founder & CEO

At 4DMT, we applied this concept to the capsid of Adeno-Associated Virus (AAV) for gene delivery. Our process starts by generating roughly a billion different capsid versions, then selecting the most effective for targeting specific cells and tissues by a preferred method of administration.

Jason Gorevic

Teladoc Health

Teladoc Health aimed to increase healthcare system capacity by leveraging underutilized physician time and overcoming location barriers.

Nick Dyer

Catalyst Clinical Research

Catalyst offers two primary solutions: Catalyst Flex and Catalyst Oncology. Catalyst Flex, built upon the foundations of Triangle Biostatistics and Catalyst Clinical Research, provides standalone services in data sciences and clinical operations across multiple therapeutic areas.

Philip Kantoff

Co-Founder & CEO

Convergent Therapeutics

Convergent is focusing on delivering targeted treatments more efficiently. We are pioneering the use of alpha particle radiation, specifically actinium-225, to target cancer cells.

Arnd Kaldowski

Sonova Group

Sonova’s hearing aids amplify sound signals to stimulate the remaining hair cells, while cochlear implants bypass these cells entirely, converting sound directly into electrical signals.

Sam Deutsch

Chief Scientific Officer

Nutcracker Therapeutics

Our platform at Nutcracker Therapeutics consists of several components: the biochip, the hardware interface, purification processes, and the software that orchestrates everything.

Sucheta Govil

Chief Commercial Officer

Covestro

North America Operations at Novo Nordisk

We are focused on forging strong partnerships and prioritizing materials that contribute to a circular economy, which allows us to maintain competitive advantage and support our customers in achieving their sustainability goals.

Doug Langa

Executive Vice President

Decades ago, Novo Nordisk took a stand that obesity is a disease, and the shame in our society needs to stop. We are committed to driving meaningful change - and it’s not just about effective medicines but other real barriers like stigma and bias. Because obesity is not a personal failing; it’s a matter of health – and people deserve respect, support and care.

Cara Brant